NCT04035434 is a Phase 1, PHASE2 clinical trial of CTX110 in B-cell Malignancy, sponsored by CRISPR Therapeutics AG.

Who is sponsoring NCT04035434?

NCT04035434 is sponsored by CRISPR Therapeutics AG.

What drugs are being tested in NCT04035434?

Interventions in NCT04035434: CTX110.

What condition does NCT04035434 study?

NCT04035434 studies B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL.

Is NCT04035434 still recruiting?

NCT04035434 is currently terminated. Last updated 24 October 2025.

Are results published for NCT04035434?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-10-24 · How we verify

NCT04035434

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Terminated Phase 1, PHASE2 Results posted Last updated 24 October 2025

What this trial tests

Phase 1, PHASE2 trial testing CTX110 in B-cell Malignancy in 93 participants. Terminated before completion.

Timeline

22 July 2019

Primary endpoint
4 October 2024

4 October 2024

Quick facts

Lead sponsor	CRISPR Therapeutics AG
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	93
Start date	22 July 2019
Primary completion	4 October 2024
Estimated completion	4 October 2024
Sites	33 locations across France, Germany, Canada, Australia, United States, Spain

Drugs / interventions tested

CTX110 — full drug profile →

Conditions studied

B-cell Malignancy — all drugs for B-cell Malignancy →
Non-Hodgkin Lymphoma — all drugs for Non-Hodgkin Lymphoma →
B-cell Lymphoma — all drugs for B-cell Lymphoma →
Adult B Cell ALL — all drugs for Adult B Cell ALL →

Sponsor

CRISPR Therapeutics AG — full company profile →

Who can join

18 and older, any sex, with B-cell Malignancy or Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population Primary · Up to 28 days

A DLT is defined as any of the following events occurring during the DLT evaluation period that persisted beyond the specified duration from onset: Grade ≥2 graft-versus-host disease (GvHD) that was steroid-refractory (e.g., progressive disease after 3 days of steroid treatment \[e.g., 1 mg/kg/day\], stable disease after 7 days, or partial response after 14 days of treatment); death during the DLT period, unless due to disease progression; Grade 4 neurotoxicity of any duration that was related or possibly related to CTX110; or any CTX110-related grade 3 or 4 toxicity deemed clinically signific

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	0
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	0
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	0
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	0

Dose Expansion Phase 1 and Phase 2: Percentage of Participants With Objective Response Rate in NHL Population Primary · Up to 5 years

The objective response rate (complete response + partial response) was analyzed as per Lugano Response Criteria for Malignant Lymphoma, as determined by independent central radiology review. For participants who received the second course of treatment, the response assessments before and after the second course are combined for the derivation of objective response. Percentages are calculated with the number of participants in the specific analysis set in each column as the denominator. Confidence intervals (CI) of percentage are calculated with Clopper-Pearson exact method.

Group	Value	95% CI
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	60.9	38.5 – 80.3
Phase 2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	75.0	34.9 – 96.8

Dose Escalation Phase 1: Percentage of Participants With Objective Response Rate in B Cell ALL Population Secondary · Up to 5 years

The objective response rate (complete response + complete remission with incomplete blood count recovery) was analyzed as per response criteria adapted from the National Comprehensive Cancer Network guidelines for treatment of acute lymphoblastic leukemia Version 2.2021, as determined by independent central radiology review. For -participants who receive the second course of treatment, the response assessments before and after the second course are combined for the derivation of objective response. Percentages are calculated with the number of participants in the specific analysis set in each

Group	Value	95% CI
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	25.0	0.6 – 80.6
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	40.0	5.3 – 85.3
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	85.7	42.1 – 99.6

Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population Secondary · Up to 5 years

Duration of response was only reported for the participants who showed objective response events. This was calculated as the time between first objective response and date of disease progression or death due to any cause. Median duration of response was calculated with the Kaplan-Meier method. Confidence intervals of median duration of response were calculated with the Brookmeyer and Crowley method with log-log transformation.

Group	Value	95% CI
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	9.20	NA – NA
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	3.75	1.68 – NA
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	3.52	0.95 – NA
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	1.02	0.46 – 1.31
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	3.60	1.91 – 8.57
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	NA	NA – NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	2.20	2.00 – NA
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	1.56	1.05 – NA

Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population Secondary · Up to 5 years

Progression-free survival (PFS) and event-free survival were calculated as the difference between date of CTX110 infusion and date of disease progression or death due to any cause. The median of PFS was calculated with the Kaplan-Meier method. The CIs of median PFS were calculated with the Brookmeyer and Crowley method with log-log transformation.

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	0.92	0.79 – NA
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	1.91	0.85 – NA
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	2.43	0.95 – NA
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	1.54	0.82 – NA
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	1.77	0.76 – 2.10
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	2.83	1.02 – 3.94
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	NA	NA – NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	2.92	0.79 – NA
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	1.94	0.92 – NA

Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population Secondary · Up to 5 years

Overall survival was calculated as the time between date of first dose of CTX110 and death due to any cause. Participants who are alive at the data cutoff date will be censored at their last date known to be alive. Median overall survival was calculated with the Kaplan-Meier method. CIs of median overall survival were calculated with the Brookmeyer and Crowley method with log-log transformation.

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	5.03	2.73 – NA
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	37.16	1.05 – NA
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	7.77	2.96 – NA
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	NA	1.61 – NA
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	5.16	1.71 – 27.73
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	14.26	4.47 – NA
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	12.12	NA – NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	7.39	1.18 – NA
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	7.62	1.71 – NA

Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population Secondary · Up to 5 years

A TEAE was any untoward medical occurrence or worsening of a pre-existing condition in a clinical trial participant who received the investigational medicinal product, regardless of a causal relationship with the treatment. An AE had to be classified as a serious adverse event (SAE) if it resulted in death, was life-threatening, required or prolonged hospitalization, caused persistent or significant disability or incapacity, led to a congenital anomaly or birth defect in a newborn, or was deemed a significant medical event by the investigator based on medical judgment.

Group	Value	95% CI
Phase1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	3
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	3
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	6
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	6
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	10
Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	34
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	1
Phase 1: Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	5
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	5
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	4
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	5
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	7

Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population Secondary · Up to 5 years

Blood samples were collected for the analysis of laboratory parameters including hematology, clinical chemistry and coagulation parameters. The hematology parameters included: Lymphocyte count decreased, Neutrophil count decreased, White blood cell decreased, Anemia, Platelet count decreased, leukocytosis and Lymphocyte count increased. Chemistry parameters included: Hypoalbuminemia, Aspartate aminotransferase increased, Alanine aminotransferase increased, Hypokalemia, Chronic kidney disease, Blood bilirubin increased, Creatinine increased, Hypermagnesemia, Hypernatremia, Hypercalcemia, Hyperk

Lymphocyte count decreased

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	3
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	3
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	6
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	6
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	10
Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	35
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	5
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	5
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	4
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	5
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	7

Neutrophil count decreased

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	3
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	3
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	6
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	6
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	10
Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	35
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	5
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	5
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	4
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	5
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	7

White blood cell decreased

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	3
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	2
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	6
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	6
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	10
Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	35
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	5
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	5
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	4
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	5
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	7

Anemia

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	1
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	4
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	3
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	8
Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	17
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	2
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	3
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	2
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	3
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	3

Platelet count decreased

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	1
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	2
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	3
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	4
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	6
Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	19
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	2
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	5
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	2
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	3
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	3

Lymphocyte count increased

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	0
Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	0
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	1
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	0
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	0

Hypoalbuminemia

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	0
Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	1
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	0
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	1
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	0

Aspartate aminotransferase increased

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	0
Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	2
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	0
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	0
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	0
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	1

Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population Secondary · Day 1 pre-infusion, Day 1 post-infusion, Day 2, Day 3, Day 5, Day 8, Day 10, Day 14, Day 21, Day 28, Month 2, Month 3, Month 6, Month 9, Month 12 and Month 24

Blood samples were collected for the analysis of mean concentration of CTX110 in blood (copies per micrograms deoxyribose nucleic acid \[DNA\]) over time following the first CTX110 infusion. Cohort A DL4a and DL4b were combined, as the same dose was administered. Mean concentration values of CTX110 have been presented by dose level.

Day 1 pre-infusion

Group	Value	95% CI
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	2.90	± 0.000
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	3.55	± 1.592
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	2.90	± NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	2.90	± 0.000
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	2.90	± 0.000
Phase 1/2: NHL: Cohort A: DL 4a + DL 4b(6x10^8 CAR+ T Cells)	3.08	± 0.934

Day 1 post-infusion

Group	Value	95% CI
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	144.95	± 147.856
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	829.37	± 1552.483
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	472.20	± NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	105.22	± 23.028
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	636.29	± 352.700
Phase 1/2: NHL: Cohort A: DL 4a + DL 4b(6x10^8 CAR+ T Cells)	979.25	± 1658.499

Day 2

Group	Value	95% CI
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	7.27	± 6.403
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	10.77	± 13.999
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	28.57	± NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	35.62	± 22.359
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	72.39	± 107.323
Phase 1/2: NHL: Cohort A: DL 4a + DL 4b(6x10^8 CAR+ T Cells)	42.39	± 101.461

Day 3

Group	Value	95% CI
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	8.36	± 5.310
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	12.46	± 9.656
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	22.03	± NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	16.76	± 13.050
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	204.43	± 300.219
Phase 1/2: NHL: Cohort A: DL 4a + DL 4b(6x10^8 CAR+ T Cells)	35.80	± 98.739

Day 5

Group	Value	95% CI
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	25.47	± 21.898
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	220.78	± 246.411
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	311.67	± NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	80.40	± 33.878
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	487.13	± 262.303
Phase 1/2: NHL: Cohort A: DL 4a + DL 4b(6x10^8 CAR+ T Cells)	770.14	± 3312.713

Day 8

Group	Value	95% CI
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	3763.68	± 8138.642
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	4337.42	± 7721.088
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	13269.43	± NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	5844.98	± 9600.631
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	719.13	± 231.318
Phase 1/2: NHL: Cohort A: DL 4a + DL 4b(6x10^8 CAR+ T Cells)	10277.87	± 27526.126

Day 10

Group	Value	95% CI
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	180.87	± 209.131
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	452.03	± 941.853
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	25719.13	± NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	19018.53	± 42303.294
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	297.91	± 248.623
Phase 1/2: NHL: Cohort A: DL 4a + DL 4b(6x10^8 CAR+ T Cells)	4056.03	± 19737.607

Day 14

Group	Value	95% CI
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	2.90	± 0.000
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	3.55	± 1.592
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	9.93	± NA
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	2435.23	± 5423.525
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	51.73	± 87.882
Phase 1/2: NHL: Cohort A: DL 4a + DL 4b(6x10^8 CAR+ T Cells)	2186.81	± 13766.282

Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population Secondary · Day 1 pre-infusion, Day 1 post-infusion, Day 2, Day 3, Day 5, Day 8, Day 10, Day 14, Day 21, Day 28, and Month 2

Blood samples were collected for the analysis of mean concentration of CTX110 in blood (copies per micrograms deoxyribose nucleic acid \[DNA\]) over time following the first CTX110 infusion.

Day 1 pre-infusion

Group	Value	95% CI
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	13.43	± 21.067
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	3.29	± 0.872
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	2.90	± 0.000

Day 1 post-infusion

Group	Value	95% CI
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	781.86	± 1395.907
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	1983.57	± 1677.746
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	602.75	± 521.357

Day 2

Group	Value	95% CI
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	4.20	± 2.252
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	93.47	± 149.220
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	18.13	± 17.532

Day 3

Group	Value	95% CI
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	13.46	± 14.905
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	20.47	± 25.356
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	7.95	± 4.705

Day 5

Group	Value	95% CI
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	28.65	± 36.011
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	42.37	± 47.444
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	62.85	± 124.743

Day 8

Group	Value	95% CI
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	71.30	± 118.215
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	16846.17	± 33459.507
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	15941.89	± 30200.959

Day 10

Group	Value	95% CI
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	226.32	± 290.508
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	26.17	± 41.517
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	14177.59	± 23256.089

Day 14

Group	Value	95% CI
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	1040.13	± 1466.869
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	2.90	± 0.000
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	380.29	± 924.424

Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population Secondary · Up to 5 years

An AE had to be classified as a serious adverse event (SAE) if it resulted in death, was life-threatening, required or prolonged hospitalization, caused persistent or significant disability or incapacity, led to a congenital anomaly or birth defect in a newborn, or was deemed a significant medical event by the investigator based on medical judgment.

Group	Value	95% CI
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	3
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	2
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	5
Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	8
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	0
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	1
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	4
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	3
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	3
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	1

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 5 years. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)

Serious: 3/3 (100%)

Deaths: 3/3

Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)

Serious: 2/3 (67%)

Deaths: 2/3

Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)

Serious: 1/6 (17%)

Deaths: 4/11

Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)

Serious: 1/6 (17%)

Deaths: 3/6

Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)

Serious: 5/10 (50%)

Deaths: 9/10

Phase 1/2: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)

Serious: 8/35 (23%)

Deaths: 21/35

Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)

Serious: 0/1 (0%)

Deaths: 1/1

Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)

Serious: 1/5 (20%)

Deaths: 3/5

Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)

Serious: 4/5 (80%)

Deaths: 4/5

Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)

Serious: 3/4 (75%)

Deaths: 4/4

Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)

Serious: 3/5 (60%)

Deaths: 2/5

Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)

Serious: 1/7 (14%)

Deaths: 1/7

Serious adverse events (47 terms)

Reaction	System	Phase 1: NHL: Cohort A Dos…	Phase 1: NHL: Cohort A: DL…	Phase 1: NHL: Cohort A: DL…	Phase 1: NHL: Cohort A: DL…	Phase 1: NHL: Cohort A: DL…	Phase 1/2: NHL: Cohort A: …	Phase 1: NHL: Cohort B: DL…	Phase 1: NHL: Cohort C: DL…	Phase 1: NHL: Cohort C: DL…	Phase 1: B Cell ALL: Cohor…	Phase 1: B Cell ALL: Cohor…	Phase 1: B Cell ALL: Cohor…
Myelodysplastic syndrome	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—	—
Cytokine release syndrome	Immune system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Immune effector cell-associated neurotoxicity syndrome	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—
Deep vein thrombosis	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—
Hypotension	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—
Neurotoxicity	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Hypertensive encephalopathy	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Pain	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Haemophagocytic lymphohistiocytosis	Immune system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Rectal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Cholecystitis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Urinary retention	Renal and urinary disorders	—	—	—	—	—	—	—	—	—	—	—	—
Haematuria	Renal and urinary disorders	—	—	—	—	—	—	—	—	—	—	—	—
Renal vein thrombosis	Renal and urinary disorders	—	—	—	—	—	—	—	—	—	—	—	—
Lower respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—
Respiratory syncytial virus infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—
Bronchopulmonary aspergillosis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (212 terms — click to expand)

Reaction	System	Phase 1: NHL: Cohort A Dos…	Phase 1: NHL: Cohort A: DL…	Phase 1: NHL: Cohort A: DL…	Phase 1: NHL: Cohort A: DL…	Phase 1: NHL: Cohort A: DL…	Phase 1/2: NHL: Cohort A: …	Phase 1: NHL: Cohort B: DL…	Phase 1: NHL: Cohort C: DL…	Phase 1: NHL: Cohort C: DL…	Phase 1: B Cell ALL: Cohor…	Phase 1: B Cell ALL: Cohor…	Phase 1: B Cell ALL: Cohor…
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Cytokine release syndrome	Immune system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Blood fibrinogen decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—
Hypophosphataemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—
Lymphopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Blood magnesium decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—
Hypotension	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—
Catheter site pain	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Pain	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—	—	—
Tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—
Immune effector cell-associated neurotoxicity syndrome	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Lethargy	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Myelodysplastic syndrome, Cytokine release syndrome, Immune effector cell-associated neurotoxicity syndrome, COVID-19, Pneumonia, Deep vein thrombosis, Hypotension, Neurotoxicity.

Data from ClinicalTrials.gov NCT04035434 adverse events section.

Sponsor's own description

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
Rafiq S, Hackett CS, Brentjens RJ. · · 2020 · cited 1111× · PMID 31848460 · DOI 10.1038/s41571-019-0297-y
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.
Wang D, Zhang F, Gao G. · · 2020 · cited 405× · PMID 32243786 · DOI 10.1016/j.cell.2020.03.023
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future.
Uddin F, Rudin CM, Sen T. · · 2020 · cited 329× · PMID 32850447 · DOI 10.3389/fonc.2020.01387
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Wang SW, Gao C, Zheng YM, Yi L, et al · · 2022 · cited 305× · PMID 35189910 · DOI 10.1186/s12943-022-01518-8
Engineering the next generation of cell-based therapeutics.
Bashor CJ, Hilton IB, Bandukwala H, Smith DM, et al · · 2022 · cited 271× · PMID 35637318 · DOI 10.1038/s41573-022-00476-6
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.
Yu AM, Choi YH, Tu MJ. · · 2020 · cited 271× · PMID 32929000 · DOI 10.1124/pr.120.019554
Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
Zhang S, Shen J, Li D, Cheng Y. · · 2021 · cited 266× · PMID 33391496 · DOI 10.7150/thno.47007
CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy.
Xu Y, Li Z. · · 2020 · cited 202× · PMID 33005303 · DOI 10.1016/j.csbj.2020.08.031

Verify or expand the search:

Other recruiting trials for B-cell Malignancy

Currently open trials in the same condition.

NCT06634589 — A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap · Phase 1, PHASE2 · recruiting
NCT05294731 — Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg · Phase 1, PHASE2 · recruiting

Other CRISPR Therapeutics AG trials

Trials by the same sponsor.

NCT05795595 — A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors · Phase 1, PHASE2 · completed
NCT05210530 — An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D · Phase 1 · completed
NCT04502446 — A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-L · Phase 1 · terminated
NCT04438083 — A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) · Phase 1 · terminated
NCT04244656 — A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04035434 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CRISPR Therapeutics AG
Last refreshed: 24 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04035434.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing